RECRUITING

Studying Health Outcomes After Treatment in Patients With Retinoblastoma

Talk to us

Conditions

RetinoblastomaCancer SurvivorBiological SiblingIntraocular RetinoblastomaUnilateral Retinoblastoma

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This trial studies health outcomes after treatment in patients with retinoblastoma. Gathering health information over time from patients and family members through vision assessments, samples of tissue and saliva, and questionnaires may help doctors learn more about what causes retinoblastoma, identify long-term health outcomes for patients with retinoblastoma, and find out which therapies may be the best for treating retinoblastoma

Official Title

Research Into Visual Endpoints and RB Health Outcomes After Treatment (RIVERBOAT)

Quick Facts

Study Start:2019-01-24
Study Completion:2031-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT03932786

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:Not specified
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Vanderbilt-Ingram Service for Timely Access
CONTACT
800-811-8480
cip@vanderbilt.edu

Principal Investigator

Debra Friedman, MD
PRINCIPAL_INVESTIGATOR
Vanderbilt Medical Center

Study Locations (Sites)

Lurie Children's Hospital
Chicago, Illinois, 60611
United States
University of Illinois, Chicago
Chicago, Illinois, 60612
United States
University of Minnesoa
Minneapolis, Minnesota, 55455
United States
Washington School of Medicine at St. Louis
Saint Louis, Missouri, 63110
United States
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229
United States
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104
United States
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, 37232
United States
MD Anderson Cancer Center
Houston, Texas, 77030
United States
Texas Childeren's Hospital
Houston, Texas, 77030
United States
Children's Hospital of Wisconsin
Milwaukee, Wisconsin, 53226
United States

Collaborators and Investigators

Sponsor: Vanderbilt-Ingram Cancer Center

  • Debra Friedman, MD, PRINCIPAL_INVESTIGATOR, Vanderbilt Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2019-01-24
Study Completion Date2031-01

Study Record Updates

Study Start Date2019-01-24
Study Completion Date2031-01

Terms related to this study

Additional Relevant MeSH Terms

  • Retinoblastoma
  • Cancer Survivor
  • Biological Sibling
  • Intraocular Retinoblastoma
  • Unilateral Retinoblastoma